
IRLAB Q3 2024 - Several catalysts ahead

Redeye returns following IRLAB's Q3 report and recent news in the company. We largely reiterate our stance and conclude that the company has several important catalysts ahead - including a Pirepemat phase IIb readout.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[IRLAB Q3 2024 - Several catalysts ahead](#)